Medication adherence and attitudes in patients with bipolar disorder and current versus past substance use disorder

PSYCHIATRY RESEARCH

卷:190

Article

Teter, Christian J.^1,2  Falone, Anthony E.^2,3  Bakaian, Amanda M.²  Tu, Chunhao¹  Oenguer, Dost⁴  Weiss, Roger D.^2,5 

[1] Univ New England, Coll Pharm, Portland, ME 04103 USA

[2] McLean Hosp, Div Alcohol & Drug Abuse, Belmont, MA 02178 USA

[3] Northeastern Univ, Boston, MA 02115 USA

[4] McLean Hosp, Schizophrenia & Bipolar Disorders Program, Belmont, MA 02178 USA

[5] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA

关键词: Mood disorder;    Addiction;    Pharmacotherapy;    Compliance;    Comorbidity;    Attitude;   

DOI  :  10.1016/j.psychres.2011.05.042

来源: Elsevier

【 摘 要 】

We examined the impact of substance use disorder (SUD) history among patients with bipolar I disorder (BD) in regards to medication-taking behaviors and attitudes. Interviews were conducted with inpatients hospitalized for BD, which included diagnostic instruments and measures of attitudes concerning psychiatric medications. We compared patients with BD and no history of SUD (BD-NH), BD and past history of SUD (BD-PH), and BD and current SUD (BD-C). The primary outcome variable was a standardized medication adherence ratio (SMAR) of [medication taken]/[medication prescribed]. Fifty-four patients with a BD diagnosis participated, which included BD-NH (n = 26), BD-PH (n = 19), and BD-C (n = 9). The SMAR was significantly different among the three groups; post-hoc analyses revealed the SMAR was significantly lower among BD-C (M = 0.70) compared to BD-NH (M = 0.90) and BD-PH (M = 0.97) patients. This finding remained significant after controlling for numerous patient characteristics. Attitudes regarding medications, measured by the Drug Attitude Inventory (DAI), were positive among a significantly higher percentage of BD-PH (89.47%) and BD-NH (65.38%) compared to BD-C (44.44%) patients. In conclusion, patients with BD-C demonstrated poor medication adherence and attitudes concerning medication management. Helping patients with BD achieve remission from SUD may lead to a more successful course of BD pharmacotherapy. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

【 授权许可】

Free